Search Results - "Godby, Kelly"

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma by Costa, Luciano J., Chhabra, Saurabh, Medvedova, Eva, Dholaria, Bhagirathbhai R., Schmidt, Timothy M., Godby, Kelly N., Silbermann, Rebecca, Dhakal, Binod, Bal, Susan, Giri, Smith, D'Souza, Anita, Hall, Aric, Hardwick, Pamela, Omel, James, Cornell, Robert F., Hari, Parameswaran, Callander, Natalie S.

“…PURPOSEThe MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal…”
Get full text

Teclistamab in patients with multiple myeloma and impaired renal function by Joiner, Laura, Bal, Susan, Godby, Kelly N., Costa, Luciano J.

“…Robust anti‐myeloma activity with teclistamab in patients with severe renal impairment…”
Get full text

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy by Gandhi, Ujjawal H., Cornell, Robert F., Lakshman, Arjun, Gahvari, Zhubin J., McGehee, Elizabeth, Jagosky, Megan H., Gupta, Ridhi, Varnado, William, Fiala, Mark A., Chhabra, Saurabh, Malek, Ehsan, Mansour, Joshua, Paul, Barry, Barnstead, Alyssa, Kodali, Saranya, Neppalli, Amarendra, Liedtke, Michaela, Narayana, Swapna, Godby, Kelly N., Kang, Yubin, Kansagra, Ankit, Umyarova, Elvira, Scott, Emma C., Hari, Parameswaran, Vij, Ravi, Usmani, Saad Z., Callander, Natalie S., Kumar, Shaji K., Costa, Luciano J.

“…The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with…”
Get full text

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma by Costa, Luciano J., Giri, Smith, Bal, Susan, Ravi, Gayathri, Godby, Kelly N.

Get full text

Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma by Bal, Susan, Giri, Smith, Godby, Kelly N., Costa, Luciano J.

Get full text

Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations by Ravi, Gayathri, Bal, Susan, Joiner, Laura, Giri, Smit, Sentell, Melissa, Hill, Tiffany, Godby, Kelly N., Costa, Luciano J.

“…Summary The combination of anti‐CD38 monoclonal antibodies to a proteasome inhibitor, an immunomodulatory agent and dexamethasone (quadruplet—QUAD) in sequence…”
Get full text

Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia by Jamy, Omer, Diebold, Kendall, Davis, Kenneth, Bachiashvili, Kimo, Rangaraju, Sravanti, Vachhani, Pankit, Godby, Kelly N., Salzman, Donna, Bhatia, Ravi

Get full text

New regimens and directions in the management of newly diagnosed multiple myeloma by Bal, Susan, Giri, Smith, Godby, Kelly N., Costa, Luciano J.

“…The introduction of novel agents over the last decade has rapidly expanded the therapeutic landscape of multiple myeloma (MM) for both transplant‐eligible and…”
Get full text

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies by Bal, Susan, Malek, Ehsan, Kansagra, Ankit, Usmani, Saad Z., Vij, Ravi, Godby, Kelly N., Cornell, Robert F., Kang, Yubin, Umyarova, Elvira, Giri, Smith, Chhabra, Saurabh, Liedtke, Michaela, Callander, Natalie S., Hari, Parameswaran, Kumar, Shaji, Costa, Luciano J.

Get full text

Revisiting the impact of immunoglobulin isotypes in multiple myeloma by Bal, Susan, Giri, Smith, Godby, Kelly N., Costa, Luciano J.

“…Association of immunoglobulin isotypes with survival in the context of modern prognostic factors has not been determined. We utilized the Flatiron Health…”
Get full text

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States by Costa, Luciano J., Brill, Ilene K., Omel, James, Godby, Kelly, Kumar, Shaji K., Brown, Elizabeth E.

“…Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that…”
Get full text

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial by Costa, Luciano J, Chhabra, Saurabh, Medvedova, Eva, Dholaria, Bhagirathbhai R, Schmidt, Timothy M, Godby, Kelly N, Silbermann, Rebecca, Dhakal, Binod, Bal, Susan, Giri, Smith, D'Souza, Anita, Hall, Aric C, Hardwick, Pamela, Omel, James, Cornell, Robert F, Hari, Parameswaran, Callander, Natalie S

“…For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes;…”
Get full text

Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality by Costa, Luciano J., Godby, Kelly N., Chhabra, Saurabh, Cornell, Robert Frank, Hari, Parameswaran, Bhatia, Smita

“…Summary The management of multiple myeloma (MM) has evolved with the increased use of autologous haematopoietic cell transplantation (AHCT) and the…”
Get full text

Real‐world applicability of commercial chimeric antigen receptor T‐cell therapy among older adults with relapsed and/or refractory multiple myeloma by Giri, Smith, Bal, Susan, Godby, Kelly N., Ravi, Gayathri, Clark, Deanna, Ubersax, Clare, Cooley, Abigail, White, Priscila, Rangarajan, Sunil, Williams, Grant R., Costa, Luciano J.

Get full text

Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features by Arnold, Kevin D., Ong, Krystle L., Ravi, Gayathri, Cutshall, Hannah, Purnell, Kalyn, Wessel, Meredith C., Godby, Kelly N., Bal, Susan, Giri, Smith, Rogers, Laura Q., Demark-Wahnefried, Wendy, Davies, Faith E., Costa, Luciano J., Morgan, Gareth J., Birmann, Brenda M., Brown, Elizabeth E.

“…Background Obesity is an established modifiable risk factor for multiple myeloma (MM). However, associations of obesity and MM risk in Black populations, for…”
Get full text

Accuracy of Medicare Claim–based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases by Sathiakumar, Nalini, Delzell, Elizabeth, Yun, Huifeng, Jooste, Rene, Godby, Kelly, Falkson, Carla, Yong, Mellissa, Kilgore, Meredith L

“…BACKGROUND:We had previously developed an algorithm for Medicare claims data to detect bone metastases associated with breast, prostate, or lung cancer. This…”
Get full text

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma by Costa, Luciano J., Lin, Yi, Cornell, R. Frank, Martin, Thomas, Chhabra, Saurabh, Usmani, Saad Z., Jagannath, Sundar, Callander, Natalie S., Berdeja, Jesus G., Kang, Yubin, Vij, Ravi, Godby, Kelly N., Malek, Ehsan, Neppalli, Amarendra, Liedtke, Michaela, Fiala, Mark, Tian, Hong, Valluri, Satish, Marino, Jennifer, Jackson, Carolyn C., Banerjee, Arnob, Kansagra, Ankit, Schecter, Jordan M., Kumar, Shaji, Hari, Parameswaran

“…In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell…”
Get full text

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy by Bal, Susan, Dhakal, Binod, Silbermann, Rebecca W., Schmidt, Timothy M., Dholaria, Bhagirathbhai, Giri, Smith, Chhabra, Saurabh, Medvedova, Eva, Godby, Kelly N., D'Souza, Anita, Hall, Aric C., Hardwick, Pamela, Omel, Jim, Cornell, Robert F., Hari, Parameswaran, Callander, Natalie S., Costa, Luciano J.

“…The incremental impact of autologous hematopoietic cell transplantation (AHCT) on disease burden with quadruplet induction in newly diagnosed multiple myeloma…”
Get full text

Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma by Wellman, Tyler J, Mudd, Sarah R, Godby, Kelly N, Wooten, Dustin W, Ross, Jeremy A, Bueno, Orlando F, Wanik, Danielle, Divgi, Chaitanya R, Comley, Robert A, Costa, Luciano J, Hesterman, Jacob Y

“…•Semi-automated 18F-FDG PET image analysis may aid measuring MM treatment response.•Semi-automated and reader-driven PET image analyses agreed in most SULpeak…”
Get full text

Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis by Anabtawi, Nadia M., Pasala, Monica Sai, Grimshaw, Alyssa A., Kharel, Prakash, Bal, Susan, Godby, Kelly, Siwakoti, Ashmita, Buford, Thomas W., Bhatia, Smita, Costa, Luciano J., Williams, Grant R., Giri, Smith

“…Background Low skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment‐related toxicities and inferior overall survival…”
Get full text